 Upon enrollment, leukapheresis will be performed for MB-CART19.1 generation. Patients with high disease burden at screening e.g. ALL with M3 marrow and 10.000L blasts in peripheral blood may receive bridging chemotherapy after leukapheresis, to avoid critical tumor lysis syndrome and cytokine release syndrome CRS by subsequent lymphodepleting chemotherapy and CAR transfer. 